Together these studies suggest that loss of Tgfβr2 expression in osteoblasts enables FGF2-mediated crosstalk with prostate cancer cells and promotes bone metastasis (Meng et al. 2018). The gene discussed is FGF2; the disease is prostate carcinoma.